Turnstone Biologics to Present Preclinical Data for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy at Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
September 28, 2023 06:00 ET
|
Turnstone Biologics Corp.
Turnstone Biologics to present preclinical data for its Selected TILs at SITC's 38th Annual Meeting.
GT Biopharma Presents Two Posters at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
November 10, 2022 15:15 ET
|
GT Biopharma, Inc.
Poster #1: Tri-specific killer engagers target natural killer cells towards mesotheliomaPoster #2: Enhancing NK cell function in the 'cold' tumor microenvironment of prostate cancer with a novel...
invIOs presents positive patient data from ongoing Phase 1b trial of APN401 cell therapy in advanced solid tumors at SITC 2022
November 10, 2022 09:40 ET
|
invIOs GmbH
Poster presentation shows treatment with APN401, an autologous cell therapy product targeting the master immune checkpoint Cbl-b, resulted in stabilization of disease for more than six months in a...
Vaccinex and its Collaborators Present Two Abstracts Related to Pepinemab Combination Immunotherapy Trials at 37th Annual Meeting of Society for Immunotherapy of Cancer
November 10, 2022 09:00 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative...
Mendus AB: Mendus presenterar data under SITC 2022 som visar DCOne-plattformens potential att expandera mördarceller (NK) för terapeutiska ändamål
November 08, 2022 02:00 ET
|
Mendus AB
STIMULERING MED DCONE-CELLER LEDER TILL SELEKTIV OCH STARK >200-FALDIG MEDIANEXPANSION AV NK CELLER MED IMMUNOLOGISKT MINNE Mendus AB (“Mendus”; IMMU.ST), ett bioläkemedelsföretag fokuserat på...
Mendus AB: Mendus to present data at SITC 2022 demonstrating the potential of the DCOne platform to expand memory NK cells for therapeutic purposes
November 08, 2022 02:00 ET
|
Mendus AB
STIMULATION WITH DCONE CELLS LEADS TO SELECTIVE AND STRONG >200-FOLD MEDIAN EXPANSION OF MEMORY NK CELLS Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies...
Lyell Immunopharma Presents New Data at SITC Highlighting its Growing Pipeline of T – Cell Reprogramming Technologies and Product Candidates Targeting Solid Tumors
November 07, 2022 08:05 ET
|
Lyell Immunopharma, Inc
Preclinical data demonstrate genetic and epigenetic reprogramming can ameliorate T cell exhaustion and enhance stem-like qualities and potency of T cells in various modalities SOUTH SAN FRANCISCO,...
Surface Oncology to Present Non-clinical Data for SRF388 and SRF114 at the Society for Immunotherapy of Cancer 2022 Annual Meeting
November 07, 2022 08:00 ET
|
Surface Oncology, Inc.
CAMBRIDGE, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...
invIOs to present data from clinical stage Cbl-b program at SITC 2022
October 18, 2022 02:00 ET
|
invIOs GmbH
VIENNA, Austria, Oct. 18, 2022 (GLOBE NEWSWIRE) -- invIOs GmbH (“invIOs”), a privately held biotechnology company developing novel therapies for cancer, today announces that two abstracts on its...
Codiak to Present New Preclinical Data Demonstrating Potent Monotherapy Activity of Two Engineered Exosome Intravenous Candidates Targeting Macrophages
October 05, 2022 08:00 ET
|
Codiak BioSciences, Inc.
– Data to be presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting – CAMBRIDGE, Mass., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK), a...